|
|
Clinical trials supported by AFM
At the present time the AFM is contributing financially to nearly 40 clinical trials – either ongoing or in preparation. They concern both neuromuscular (approx 50%) and non-neuromuscular diseases :
- 11 neuromuscular diseases
- 4 neurological or neurodegenerative diseases: adrenoleukodystrophy, Huntington disease, Friedreich ataxia and San Filippo disease (2 different types)
- 3 blood diseases: drepanocytosis, beta-thalassemia and porphyria
- 2 immune deficiencies: ADA and WASP
- 1 skin disease: epidermolysis bullosa (2 different forms)
- 1 eye disease: Leber Amaurosis
- 1 ageing disease: progeria
- myocardial infarction
These trials are distributed between :
- gene therapy (50%) to correct genetic mutations and produce missing or deficient proteins
- cell therapy to regenerate diseased tissue (20%)
- classic pharmacology (30%) with molecules already used for other diseases but likely to be beneficial for neuromuscular diseases, or new molecules likely to attack directly the cause or the consequences of genetic damage.
|
| 
Print.
Send.